"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009025
|
| MeSH Number(s) |
D03.383.533.640
|
| Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 6 | 7 |
| 2015 | 1 | 3 | 4 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Glioma-induced alterations in excitatory neurons are reversed by mTOR inhibition. Neuron. 2025 Mar 19; 113(6):858-875.e10.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol. 2024 Aug; 17(8):445-465.
-
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 10 24; 391(16):1486-1498.
-
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024 Jun; 9(6):103488.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Expanding Complex Morpholines Using Systematic Chemical Diversity. Org Lett. 2024 May 03; 26(17):3493-3497.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. Cell Death Dis. 2024 01 22; 15(1):80.
-
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):105-121.